A new treatment for refractory multiple myeloma

July 14, 2019

healthysoch

New Delhi, July 14, 2019 :

Selinexor (Xpovio) tablet in combination with dexamethasone has received FDA approval as treatment option for the adult patients with multiple myeloma with no available therapy.

Indication: Treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

Side effects: Leukopenia, neutropenia, thrombocytopenia, anemia, vomiting, nausea, fatigue, diarrhea, fever, decreased appetite and weight, constipation, upper respiratory tract infections and hyponatremia.

Precautions

  • Monitor patients for low blood counts, platelets and sodium levels.
  • Avoid taking this drug along with other medications that may cause dizziness or confusion and avoid situations where dizziness may be a problem.
  • Health care professionals should optimize the patient’s hydration status, blood counts and other medications to avoid dizziness or confusion.

(Source: FDA)

Author : Dr KK AggarwalPadma Shri Awardee

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

Aster DM Healthcare Launches ‘Our New Earth’ Microsite to Coach People to Transition to the ‘New Normal’ living post lock-down

‘Our New Earth’ microsite https://www.ournew.earth/ is a health, wellness and development focused

Antibiotic resistance rapidly spreading around the world

“These resistant bacteria can lead to severe infections and mortality